Login to Your Account


PhRMA Reports Tout 5,400 Compounds in 'Robust' Pipeline

By Marie Powers
Staff Writer

Thursday, January 17, 2013
The Pharmaceutical Research and Manufacturers of America (PhRMA) served up two reports Thursday touting U.S. biopharma's "innovative and robust" pipeline of some 5,400 new molecular entities (NMEs), including more than 800 in Phase III studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription